Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Payables (2017 - 2024)

Solid Biosciences' Payables history spans 8 years, with the latest figure at $3.5 million for Q3 2024.

  • For Q3 2024, Payables rose 82.19% year-over-year to $3.5 million; the TTM value through Sep 2024 reached $3.5 million, up 82.19%, while the annual FY2023 figure was $2.0 million, 37.25% down from the prior year.
  • Payables for Q3 2024 was $3.5 million at Solid Biosciences, up from $2.5 million in the prior quarter.
  • Across five years, Payables topped out at $5.6 million in Q1 2023 and bottomed at $1.7 million in Q1 2024.
  • The 5-year median for Payables is $3.2 million (2022), against an average of $3.5 million.
  • The largest YoY upside for Payables was 82.19% in 2024 against a maximum downside of 69.08% in 2024.
  • A 5-year view of Payables shows it stood at $3.3 million in 2020, then soared by 36.32% to $4.5 million in 2021, then decreased by 27.45% to $3.2 million in 2022, then plummeted by 37.25% to $2.0 million in 2023, then surged by 70.18% to $3.5 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Payables are $3.5 million (Q3 2024), $2.5 million (Q2 2024), and $1.7 million (Q1 2024).